Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

• Status: Completed
• Trial end date: 2012-03-05

Summary

A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily Alendronate therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Amgen
• Treatments: Alendronate; Denosumab; Etidronic Acid; Risedronate Sodium; Risedronic Acid